Highnoon Laboratories products and prices in Pakistan
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Public listed pharmaceutical manufacturer · Lahore · Pakistan
Publicly listed Lahore pharmaceutical manufacturer with a broad therapeutic portfolio, research and development operations and national distribution.
Highnoon Laboratories products in Pakistan
Highnoon Laboratories Ltd has 155 medicine presentations registered in Pakistan under 65 brands, covering 50 generic medicines. Most of its products are in Anti-infectives, Respiratory & allergy and Hematology & thrombosis. Its brands with the most registered strengths and packs are Combivair (Budesonide + Formoterol), Amonate (Artesunate + Amodiaquine), Rivaro (Rivaroxaban) and Emesson (Ondansetron). 155 products have an official DRAP price on MedInfoBase. See all 65 brands A to Z
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Highnoon Laboratories Limited
- Company type
- Public listed pharmaceutical manufacturer
- Address
- 17.5 KM, Multan Road, Lahore 53700, Pakistan · 53700
- Website
- highnoon-labs.com ↗
- Phone
- +92 42 111 000 465
- info@highnoon.com.pk
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Highnoon Laboratories Ltd is priced against the market
105 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Combivair | Budesonide + Formoterol | 400 mcg + 6 mcg | Inhalation capsule | 30 | 054317 | PKR 681.09 | PKR 22.70/capsule | No comparator |
| Combivair | Budesonide + Formoterol | 6 mcg + 400 mcg | Inhalation capsule | 50's | 054317 | PKR 1,112.45 | PKR 22.25/capsule | No comparator |
| Combivair | Budesonide + Formoterol | 6 mcg + 400 mcg | Inhalation capsule | 60 | 054317 | PKR 1,334.95 | PKR 22.25/capsule | No comparator |
| Combivair | Budesonide + Formoterol | 6 mcg + 400 mcg | Inhalation capsule | 40's | 054317 | PKR 889.96 | PKR 22.25/capsule | No comparator |
| Combivair Forte | Budesonide + Formoterol | 400 mcg + 12 mcg | Inhalation capsule | 30 | 107193 | PKR 690.31 | PKR 23.01/capsule | 🔒 Pharma Pro |
| Combivair Forte | Budesonide + Formoterol | 400 mcg + 12 mcg | Inhalation capsule | 60 | 107193 | PKR 1,353.00 | PKR 22.55/capsule | 🔒 Pharma Pro |
| Combivair Forte | Budesonide + Formoterol | 400 mcg + 12 mcg | Inhalation capsule | 40 | 107193 | PKR 902.01 | PKR 22.55/capsule | 🔒 Pharma Pro |
| Combivair Forte | Budesonide + Formoterol | 400 mcg + 12 mcg | Inhalation capsule | 50 | 107193 | PKR 1,127.51 | PKR 22.55/capsule | 🔒 Pharma Pro |
| Cyrocin | Ciprofloxacin | 250 mg | Tablet | 10 | 011406 | PKR 364.67 | PKR 36.47/tablet | 🔒 Pharma Pro |
| Cyrocin | Ciprofloxacin | 500 mg | Tablet | 10 | 011407 | PKR 679.78 | PKR 67.98/tablet | 🔒 Pharma Pro |
| Cyrocin | Ciprofloxacin | 750 mg | Tablet | 10 | 038499 | PKR 458.54 | PKR 45.85/tablet | 🔒 Pharma Pro |
| Cyrocin | Ciprofloxacin | 250 mg/5 mL | Suspension | 60 ml | 071579 | PKR 330.46 | PKR 5.51/mL | 🔒 Pharma Pro |
| Cyrocin | Ciprofloxacin | 125 mg/5 mL | Suspension | 60 ml | 071580 | PKR 222.36 | PKR 3.71/mL | 🔒 Pharma Pro |
| Cytarabine Injection | Cytarabine | 100 mg | Injection | 1 | 016169 | PKR 349.99 | — | No comparator |
| Daclata | Daclatasvir | 30 mg | Tablet | 28 | 089434 | PKR 5,223.91 | PKR 186.57/tablet | 🔒 Pharma Pro |
| Daclata | Daclatasvir | 60 mg | Tablet | 28 | 089435 | PKR 9,530.12 | PKR 340.36/tablet | 🔒 Pharma Pro |
| Defal | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6 | 067821 | PKR 682.48 | PKR 113.75/tablet | 🔒 Pharma Pro |
| Diajard | Empagliflozin | 10 mg | Tablet | 20 | 106568 | PKR 1,473.62 | PKR 73.68/tablet | 🔒 Pharma Pro |
| Diajard | Empagliflozin | 10 mg | Tablet | 14 | 106568 | PKR 1,052.59 | PKR 75.19/tablet | 🔒 Pharma Pro |
| Diajard | Empagliflozin | 25 mg | Tablet | 20 | 106582 | PKR 1,763.81 | PKR 88.19/tablet | 🔒 Pharma Pro |
| Diajard | Empagliflozin | 25 mg | Tablet | 14 | 106582 | PKR 1,259.87 | PKR 89.99/tablet | 🔒 Pharma Pro |
| Diajard Forte XR 10mg/5mg/1000mg TabletRegistry verified | Empagliflozin, Linagliptin, Metformin HCI | — | — | — | 121663Official source ↗ | No indexed price | — | — |
| Diajard Forte XR 12.5mg/2.5mg/1000mg TabletRegistry verified | Empagliflozin, Linagliptin, Metformin HCI | — | — | — | 121664Official source ↗ | No indexed price | — | — |
| Diajard Forte XR 25mg/5mg/1000mg TabletRegistry verified | Empagliflozin, Linagliptin, Metformin HCI | — | — | — | 121665Official source ↗ | No indexed price | — | — |
| Diajard Forte XR 5mg/2.5mg/1000mg TabletRegistry verified | Empagliflozin, Linagliptin, Metformin HCI | — | — | — | 121662Official source ↗ | No indexed price | — | — |
| Diajard-L 5/10mg TabletRegistry verified | Empagliflozin, Linagliptin | — | — | — | 124265Official source ↗ | No indexed price | — | — |
| Diajard-L 5/25mg TabletRegistry verified | Empagliflozin, Linagliptin | — | — | — | 124264Official source ↗ | No indexed price | — | — |
| Diajard-M 12.5/1000mg TabletRegistry verified | Empagliflozin, Metformin hydrochloride | — | — | — | 106612Official source ↗ | No indexed price | — | — |
| Diajard-M 12.5/500mg TabletRegistry verified | Empagliflozin, Metformin hydrochloride | — | — | — | 106583Official source ↗ | No indexed price | — | — |
| Diajard-M 5/1000mg TabletRegistry verified | Empagliflozin, Metformin hydrochloride | — | — | — | 106584Official source ↗ | No indexed price | — | — |
| Diajard-MXR 10/1000mg TabletRegistry verified | Empagliflozin (as immediate release layer), Metformin HCl (as sustained release layer) | — | — | — | 106283Official source ↗ | No indexed price | — | — |
| Diajard-MXR 12.5/1000mg TabletRegistry verified | Empagliflozin (as immediate release layer), Metformin HCl (as sustained release layer) | — | — | — | 106284Official source ↗ | No indexed price | — | — |
| Diajard-MXR 25/1000mg TabletRegistry verified | Empagliflozin (as immediate release layer), Metformin hydrochloride (as extended release) | — | — | — | 106285Official source ↗ | No indexed price | — | — |
| Diajard-MXR 5/1000mg TabletRegistry verified | Empagliflozin (as immediate release layer), Metformin HCl (as sustained release layer) | — | — | — | 106282Official source ↗ | No indexed price | — | — |
| Diuvir 200/ Lopinavir + RitonavirSource observed | — | 50 mg | Tablet | 120 | 109293Official source ↗ | No indexed price | — | — |
| Diuvir 200/50 mg Tablet Lopinavir 200 mg + Ritonavir 20 mgSource observed | — | — | — | 120 | 109293Official source ↗ | No indexed price | — | — |
| Dongsulin 70/30Source observed | Human insulin premix 30/70 (30% regular + 70% NPH) | 100 IU/mL | Injection | 10 ml | 039880Official source ↗ | No indexed price | — | — |
| Dongsulin 70/30Source observed | Human insulin premix 30/70 (30% regular + 70% NPH) | 300 IU/3 mL | Suspension for injection | 3 ml Catridge | 041121Official source ↗ | No indexed price | — | — |
| Dongsulin 70/30 10 ml vial Recombinant Human Insulin 1000 IUSource observed | — | — | — | 10 ml | 039880Official source ↗ | No indexed price | — | — |
| Dongsulin N | Human insulin (isophane/NPH) | 100 IU/mL (1000 IU/10 mL) | Suspension for injection | 1 | 039881 | PKR 1,030.44 | — | No comparator |
| Dongsulin N | Human insulin (isophane/NPH) | 300 IU/3 mL | Suspension for injection | 3 ml Catridge | 041122 | PKR 351.77 | PKR 117.26/mL | No comparator |
| Dongsulin R | Regular human insulin | 100 IU/mL (1000 IU/10 mL) | Solution for injection | 1 | 039879 | PKR 1,030.44 | — | No comparator |
| Dongsulin R | Regular human insulin | 300 IU/3 mL | Solution for injection | 3 ml Catridge | 041120 | PKR 351.77 | PKR 117.26/mL | No comparator |
| Efix | Cefixime | 400 mg | Capsule | 5 | 059519 | PKR 548.67 | PKR 109.73/capsule | 🔒 Pharma Pro |
| Efix dry | Cefixime | 100 mg/5 mL | Dry suspension | 30ML | 059520 | PKR 330.39 | PKR 11.01/mL | 🔒 Pharma Pro |
| Efix DS Dry | Cefixime | 200 mg/5 mL | Dry suspension | 30 ML | 084825 | PKR 404.31 | PKR 13.48/mL | 🔒 Pharma Pro |
| Emesson | Ondansetron | 4 mg | Tablet | 10 | 110632 | PKR 767.30 | PKR 76.73/tablet | 🔒 Pharma Pro |
| Emesson | Ondansetron | 4 mg/5 mL | Oral solution | 50ml | 110633 | PKR 743.51 | PKR 14.87/mL | 🔒 Pharma Pro |
| Emesson | Ondansetron | 8 mg | Tablet | 10 | 110634 | PKR 1,278.84 | PKR 127.88/tablet | 🔒 Pharma Pro |
| Emesson | Ondansetron | 8 mg | Injection | 5 | 110635 | PKR 3,843.95 | — | No comparator |
All 65 Highnoon Laboratories brands in Pakistan
- 5-FU Fluorouracil (5-FU) · 250 mg injection, 500 mg injection
- Alkyloxan Cyclophosphamide · 200 mg injection
- Amonate Artesunate + Amodiaquine · 100 mg + 270 mg tablet, 25 mg + 67.5 mg tablet, 50 mg + 135 mg tablet
- Apiban Apixaban · 2.5 mg tablet, 5 mg tablet
- Artecxin Artemether + Lumefantrine · 20 mg + 120 mg tablet, 40 mg + 240 mg tablet
- Artecxin plus Artemether + Lumefantrine · 80 mg + 480 mg tablet
- Asthavent 100 Salbutamol · 100 mcg inhalation
- Benzisox Risperidone · 1 mg tablet, 2 mg tablet, 3 mg tablet
- Breavent Salbutamol · 200 mcg inhalation
- Budeform 100 Budesonide · 100 mcg inhalation
- Budeform 200 Budesonide · 200 mcg inhalation
- Budevair Budesonide · 100 mcg inhalation, 200 mcg inhalation, 400 mcg inhalation
- Cisplatin Cisplatin · 10 mg injection
- Cisplatin Injection Cisplatin · 50 mg injection
- Combivair Budesonide + Formoterol · 100 mcg + 6 mcg inhalation, 200 mcg + 6 mcg inhalation, 400 mcg + 6 mcg inhalation
- Combivair Forte Budesonide + Formoterol · 400 mcg + 12 mcg inhalation
- Cyrocin Ciprofloxacin · 125 mg/5 mL suspension, 250 mg tablet, 250 mg/5 mL suspension
- Cytarabine Injection Cytarabine · 100 mg injection
- Daclata Daclatasvir · 30 mg tablet, 60 mg tablet
- Defal Artemether + Lumefantrine · 80 mg + 480 mg tablet
- Diajard Empagliflozin · 10 mg tablet, 25 mg tablet
- Dongsulin N Human insulin (isophane/NPH) · 100 IU/mL (1000 IU/10 mL) injection, 300 IU/3 mL injection
- Dongsulin R Regular human insulin · 100 IU/mL (1000 IU/10 mL) injection, 300 IU/3 mL injection
- Efix Cefixime · 400 mg capsule
- Efix dry Cefixime · 100 mg/5 mL suspension
- Efix DS Dry Cefixime · 200 mg/5 mL suspension
- Emesson Ondansetron · 4 mg injection, 4 mg tablet, 4 mg/5 mL solution
- Envir Entecavir · 0.5 mg tablet, 1 mg tablet
- Foracort 100 Budesonide + Formoterol · 100 mcg + 6 mcg inhalation
- Foracort 200 Budesonide + Formoterol · 200 mcg + 6 mcg inhalation
- Fosbu Sofosbuvir · 400 mg tablet
- Fosbu V Sofosbuvir + Velpatasvir · 400 mg + 100 mg tablet
- Fosbu V 400 Sofosbuvir + Velpatasvir · 100 mg + 100 mg tablet
- Hi-Multivit Vitamin A, Vitamin A + Vitamin D + Thiamine + Riboflavin + Nicotinamide + Vitamin C · 2500 IU tablet, 2500 IU + 300 IU + 1 mg + 0.5 mg + 7.5 mg + 15 mg tablet
- Hifarin Warfarin · 5 mg tablet
- Hitase Letrozole · 2.5 mg tablet
- Hitecxin ACT Dihydroartemisinin + Piperaquine · 40 mg + 320 mg tablet
- Hitrazole Itraconazole · 100 mg tablet
- Ipratec Ipratropium bromide · 0.025 % solution, 18 mcg inhalation
- Lexopine Carbamazepine · 100 mg syrup, 200 mg tablet
- Loprin Acetylsalicylic acid (Aspirin) · 150 mg tablet, 300 mg tablet, 75 mg tablet
- Mectin Ivermectin · 3 mg tablet
- Misar-AM Telmisartan + Amlodipine · 40 mg + 10 mg tablet, 40 mg + 5 mg tablet, 80 mg + 5 mg tablet
- Misar-AM 80/10 Telmisartan + Amlodipine · 80 mg + 10 mg tablet
- Misar-H Telmisartan + Hydrochlorothiazide · 40 mg + 12.5 mg tablet, 80 mg + 12.5 mg tablet, 80 mg + 25 mg tablet
- MTX Methotrexate · 2.5 mg tablet, 50 mg injection
- Novirin Ribavirin · 100 mg capsule, 200 mg capsule, 400 mg capsule
- Nystatin Oral Nystatin · 100000 IU/mL drops
- Opinil Naltrexone · 50 mg tablet
- Oxaquin Moxifloxacin · 400 mg tablet
- Paratol Paracetamol · 500 mg tablet
- Pidogrel Clopidogrel · 75 mg tablet
- Pospenem Meropenem · 500 mg injection
- Prepenem Imipenem + Cilastatin · 500 mg + 500 mg injection
- Rivaro Rivaroxaban · 10 mg tablet, 15 mg tablet, 2.5 mg tablet
- Sprahaler Ipratropium bromide · 500 mcg inhalation
- Sprahaler 20 Ipratropium bromide · 20 mcg inhalation
- Termibex Amoxicillin + clavulanic acid · 1 g + 0.2 g injection
- Tiovair Tiotropium · 18 mcg inhalation
- Unitinase Streptokinase · 1.5 million IU injection, 750,000 IU injection
- Urotoin Nitrofurantoin · 100 mg tablet
- Voxiquin Levofloxacin · 250 mg tablet, 500 mg tablet
- Xormet XR Metformin · 1000 mg tablet, 500 mg tablet, 750 mg tablet
- Zolebid Sulfamethoxazole + Trimethoprim · 80 mg + 400 mg suspension
- Zolebid DS Sulfamethoxazole + Trimethoprim · 800 mg + 160 mg tablet
Highnoon Laboratories: common questions
How many products does Highnoon Laboratories have in Pakistan?
Highnoon Laboratories Ltd has 155 registered medicine presentations in Pakistan, sold under 65 brands and covering 50 generic medicines.
What are the main brands of Highnoon Laboratories?
By number of registered strengths and packs, its largest brands are Combivair (Budesonide + Formoterol), Amonate (Artesunate + Amodiaquine), Rivaro (Rivaroxaban), Emesson (Ondansetron) and Misar-AM (Telmisartan + Amlodipine). This is not a sales ranking.
Which therapy areas does Highnoon Laboratories cover?
The most products are in Anti-infectives (50), Respiratory & allergy (32), Hematology & thrombosis (21), Cardiovascular (13) and Oncology & immunology (11).
Where can I see Highnoon Laboratories medicine prices?
Open any brand in the list above for its official DRAP price, pack sizes, price history and other brands of the same medicine.
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.